1. Scrip
  2. >>Business
  3. >>Strategy

A Look Into The Future Of NASH

 
• By Elizabeth Cairns

The liver disease is one of the hottest areas of drug development. Here are some upcoming catalysts to look out for.

Liver disease
A plethora of drug candidates are in development for NASH

Sometimes advances in drug development are like London buses: you wait for ages, and then loads turn up at once. This has certainly been the case in the non-alcoholic steatohepatitis (NASH) space recently, with several mid-stage trials yielding positive – or positive-ish – data in the past few months.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

 
• By Joseph Haas

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.

Soriot Cautions Europe Amid More US Expansion

 
• By Kevin Grogan

The AstraZeneca CEO again calls for rich European countries to pay more for new drugs because "a model where the US funds innovation in our industry for the entire world doesn't work."

AstraZeneca’s Truqap Trips Up In Prostate Cancer Study

 
• By Kevin Grogan

The AKT inhibitor proves ineffective for metastatic castration-resistant disease in a Phase III trial.

More from Business

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

 
• By Joseph Haas

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.

Another CRL Prompts Questions About Regeneron’s Regulatory Operations

 
• By Alaric DeArment

CEO Len Schleifer explained on the company’s Q1 earnings call that most of the complete response letters the company has received related to third-party suppliers, not efficacy or safety.

Novartis Doubles Down On Push For Higher Drug Prices In Europe

 
• By Jessica Merrill

CEO Vas Narasimhan urged European governments to spend more to support drug innovation during Novartis's first-quarter results call.